ArticleEndocrine-related cancer2010
Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.
Article in Endocrine-related cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.Breast cancer research and treatment · 2017Trial
- Network pharmacology analysis reveals potential targets and mechanisms of proton pump inhibitors in breast cancer with diabetes.Scientific reports · 2023Article
- Hyperinsulinaemia in cancer.Nature reviews. Cancer · 2020Review
- Using Phosphatidylinositol Phosphorylation as Markers for Hyperglycemic Related Breast Cancer.International journal of molecular sciences · 2020Article
- Obesity, Type 2 Diabetes, and Cancer Risk.Frontiers in oncology · 2020Review
- A Review on Dietary Intervention in Obesity Associated Colon CancerAsian Pacific journal of cancer prevention : APJCP · 2019Review
- Diabetes, Obesity, and Breast Cancer.Endocrinology · 2018Review
- OP449 inhibits breast cancer growth without adverse metabolic effects.Endocrine-related cancer · 2017Article
- Revisiting the IGF-1R as a breast cancer target.NPJ precision oncology · 2017Article
- EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.Endocrine-related cancer · 2016Article
- Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes.BMC cancer · 2015Article
- CD24(+) cells fuel rapid tumor growth and display high metastatic capacity.Breast cancer research : BCR · 2015Article
- Highly specific role of the insulin receptor in breast cancer progression.Endocrine-related cancer · 2015Article
- TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Cell death & disease · 2013Review
- Insulin and IGFs in obesity-related breast cancer.Journal of mammary gland biology and neoplasia · 2013Review
- Social disparities, health risk behaviors, and cancer.BMC surgery · 2013Article
- Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Oncotarget · 2012Article
- Obesity and cancer risk: evidence, mechanisms, and recommendations.Annals of the New York Academy of Sciences · 2012Review
- Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.Oncogene · 2012Article
- Insulin-like growth factor receptor inhibitors: baby or the bathwater?Journal of the National Cancer Institute · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Type 2 diabetes increases breast cancer risk and mortality, and hyperinsulinemia is a major mediator of this effect. The mammalian target of rapamycin (mTOR) is activated by insulin and is a key regulator of mammary tumor progression. Pharmacological mTOR inhibition suppresses tumor growth in numerous mammary tumor models in the non-diabetic setting. However, the role of the mTOR pathway in type 2 diabetes-induced tumor growth remains elusive. Herein, we investigated whether the mTOR pathway is implicated in insulin-induced mammary tumor progression in a transgenic mouse model of type 2 diabetes (MKR mice) and evaluated the impact of mTOR inhibition on the diabetic state. Mammary tumor progression was studied in the double transgenic MMTV-Polyoma Virus middle T antigen (PyVmT)/MKR mice and by orthotopic inoculation of PyVmT- and Neu/ErbB2-driven mammary tumor cells (Met-1 and MCNeuA cells respectively). mTOR inhibition by rapamycin markedly suppressed tumor growth in both wild-type and MKR mice. In diabetic animals, however, the promoting action of insulin on tumor growth was completely blunted by rapamycin, despite a worsening of the carbohydrate and lipid metabolism. Taken together, pharmacological mTOR blockade is sufficient to abrogate mammary tumor progression in the setting of hyperinsulinemia, and thus mTOR inhibitors may be an attractive therapeutic modality for breast cancer patients with type 2 diabetes. Careful monitoring of the metabolic state, however, is important as dose adaptations of glucose- and/or lipid-lowering therapy might be necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.